Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
18.58
+0.34 (1.89%)
Oct 15, 2025, 3:53 PM EDT - Market open
Zymeworks Revenue
Zymeworks had revenue of $48.73M in the quarter ending June 30, 2025, with 153.21% growth. This brings the company's revenue in the last twelve months to $122.87M, up 95.94% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$122.87M
Revenue Growth
+95.94%
P/S Ratio
11.18
Revenue / Employee
$429,605
Employees
286
Market Cap
1.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZYME News
- 1 day ago - Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference - GlobeNewsWire
- 6 days ago - InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors - Newsfile Corp
- 6 days ago - Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - GlobeNewsWire
- 6 weeks ago - Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On - Seeking Alpha
- 6 weeks ago - Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - Benzinga
- 6 weeks ago - Zymeworks halts development of cancer drug after trial setback - Reuters
- 6 weeks ago - Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - GlobeNewsWire
- 2 months ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire